Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 31:3:261.
doi: 10.12688/f1000research.5564.1. eCollection 2014.

Collaboration for rare disease drug discovery research

Affiliations

Collaboration for rare disease drug discovery research

Nadia K Litterman et al. F1000Res. .

Abstract

Rare disease research has reached a tipping point, with the confluence of scientific and technologic developments that if appropriately harnessed, could lead to key breakthroughs and treatments for this set of devastating disorders. Industry-wide trends have revealed that the traditional drug discovery research and development (R&D) model is no longer viable, and drug companies are evolving their approach. Rather than only pursue blockbuster therapeutics for heterogeneous, common diseases, drug companies have increasingly begun to shift their focus to rare diseases. In academia, advances in genetics analyses and disease mechanisms have allowed scientific understanding to mature, but the lack of funding and translational capability severely limits the rare disease research that leads to clinical trials. Simultaneously, there is a movement towards increased research collaboration, more data sharing, and heightened engagement and active involvement by patients, advocates, and foundations. The growth in networks and social networking tools presents an opportunity to help reach other patients but also find researchers and build collaborations. The growth of collaborative software that can enable researchers to share their data could also enable rare disease patients and foundations to manage their portfolio of funded projects for developing new therapeutics and suggest drug repurposing opportunities. Still there are many thousands of diseases without treatments and with only fragmented research efforts. We will describe some recent progress in several rare diseases used as examples and propose how collaborations could be facilitated. We propose that the development of a center of excellence that integrates and shares informatics resources for rare diseases sponsored by all of the stakeholders would help foster these initiatives.

Keywords: Twitter; drug discovery; patient advocacy; rare disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: S.E. works for Collaborations in Chemistry, and consults for Collaborative Drug Discovery Inc. as well as rare disease groups including the Hereditary Neuropathy Foundation, Hannah's Hope Fund and Phoenix Nest. N.K.L. works for Collaborative Drug Discovery Inc. M.R. works for National Brain Tumor Society. D.C.S. works for the Institute for Rare & Neglected Diseases Drug Discovery.

Figures

Figure 1.
Figure 1.. An illustration of the pieces of the rare disease jigsaw that could be brought together for developing treatments more efficiently.

Similar articles

Cited by

References

    1. Melnikova I: Rare diseases and orphan drugs. Nat Rev Drug Discov. 2012;11(4):267–8. 10.1038/nrd3654 - DOI - PubMed
    1. Field MJ, Boat TF: Rare Diseases and Orphan Products: Accelerating Research and Development. Washington DC: The National Academics Press.2011. Reference Source - PubMed
    1. Swinney DC, Xia S: The discovery of medicines for rare diseases. Future Med Chem. 2014;6(9):987–1002. 10.4155/fmc.14.65 - DOI - PMC - PubMed
    1. DiVincenzo C, Elzinga CD, Medeiros AC, et al. : The allelic spectrum of Charcot–Marie–Tooth disease in over 17,000 individuals with neuropathy. Mol Genet Genomic Med. 2014. In press. 10.1002/mgg3.106 - DOI - PMC - PubMed
    1. Grabowski P, Briest F, Baum RP, et al. : Vandetanib therapy in medullary thyroid cancer. Drugs Today (Barc). 2012;48(11):723–33. - PubMed

LinkOut - more resources